Is Carlsmed, Inc. (CARL) Overvalued?
We dive into why Carlsmed, Inc. (CARL) could be considered overvalued on 2026-08-17, based on AAII’s Value Score and Grade.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.
Commentary & Analysis
Why Carlsmed, Inc.’s (CARL) Stock Is Up 9.44%
As of Thursday, August 06, Carlsmed, Inc.’s CARL share price has surged by 9.44%, which has investors questioning if this is right time to sell.Michael Rose
What You Need to Know About Carlsmed, Inc.'s Q3 Earnings
Carlsmed, Inc.'s fiscal Q3 earnings report was released on Wednesday, August 05. Let's dive in to see if (CARL) missed or beat analyst's expectations.Michael Rose
Why Carlsmed, Inc.’s (CARL) Stock Is Up 5.48%
As of Monday, August 03, Carlsmed, Inc.’s CARL share price has surged by 5.48%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Carlsmed, Inc.’s (CARL) Stock Is Up 8.12%
As of Tuesday, July 28, Carlsmed, Inc.’s CARL share price has surged by 8.12%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | CARL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $450.8 | $407.7 | 36% |
|
| Shares Out (Mil) | 27.2 | 41.3 | 35% |
|
| Institutional Ownership | 69.4% | 81.4% | 42% |
|
| Float (Mil) | 15.7 | 34.9 | 25% |
|
| Beta | na | 0.88 | na |
|
| Avg Daily Volume (000s) | 172 | 412 | 42% |
|
| Price Change (52-week) |
31.6% | 64.8% | 70% |
|
| Growth | CARL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 11.8% | na |
|
| Net Income (5yr) | na | (6.0%) | na |
|
| EPS (5yr) | na | 10.4% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (16.2%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.385) | ($1.410) | ($1.380) | |
| Month Ago EPS | ($0.395) | ($1.465) | ($1.435) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.395) | ($1.465) | ($1.435) | |
| Year/Year Chg | (0.5%) | (33.6%) | (47.8%) | |
| Financials | CARL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $63 | $119 | 22% |
|
| Net Income (TTM) (Mil) | ($36) | ($9) | 19% |
|
| EPS (TTM) | ($1.425) | ($0.400) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($34) | ($3) | 12% |
|
| Net Cash Flow (TTM) (Mil) | $13 | $1 | 58% |
|
| Long-Term Debt (Q1) (Mil) | $21 | $21 | 33% |
|
| Enterprise Value (Q1) (Mil) | na | $427 | na |
|
| Valuation | CARL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.34 | 3.06 | 79% |
|
| P/E | na | 27.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.7 | na |
|
| Ratios | CARL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 76.6% | 58.9% | 86% |
|
| Net Margin | (57.4%) | (6.9%) | 11% |
|
| ROA | (42.4%) | (12.7%) | 13% |
|
| ROE | na | (13.1%) | na |
|
| Liabilities to Assets | 28.7% | 46.0% | 20% |
|
| F-Score | 3 | 4 | 18% |
|
Carlsmed, Inc. did not pass any screens on 8/20/2026.
